Glycolipid ester-type heterodimers from Ipomoea tyrianthina and their pharmacological activity

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4652-4656

  León Rivera, Ismael ^a   Mirón López, Gumersindo ^b   Estrada Soto, Samuel ^c   Aguirre Crespo, Francisco ^c   Gutiérrez, María del Carmen ^c   Molina Salinas, Gloria María ^d   Hurtado, Gerardo ^e   Navarrete Vázquez, Gabriel ^c   Montiel, Elizur ^c  

^a CENTRO DE INVESTIGACIONES QUÍMICAS   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

GABA; Glycolipid; Ipomoea tyrianthina; Vasorelaxant

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLYCOLIPID; HETERODIMER; MONOMER; PLANT EXTRACT; REAGENT; SCAMMONIC ACID A; TETRASACCHARIDE; TYRIANTHIN A; TYRIANTHIN B; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AORTA; ARTICLE; BRAIN CORTEX; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; DRUG STRUCTURE; ENDOTHELIUM; IC 50; IN VITRO STUDY; IPOMOEA; IPOMOEA TYRIANTHINA; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; VASODILATATION;

ANIMALS; ANTITUBERCULAR AGENTS; DIMERIZATION; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLYCOLIPIDS; IPOMOEA; MICE; PLANT ROOTS; RATS; VASODILATOR AGENTS;

IPOMOEA; RATTUS;

EID: 67651102822     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.087     Document Type: Article

References (21)

1. Martínez M. Las Plantas Medicinales de México (1990), Ediciones Botas, México p 276
2. Mirón-López G., Herrera-Ruiz M., Estrada-Soto S., Aguirre-Crespo F., Vázquez-Navarrete L., and León-Rivera I. J. Nat. Prod. 70 (2007) 557
3. Hernández-Carlos B., Bye R., and Pereda-Miranda R. J. Nat. Prod. 62 (1999) 1096
4. Pereda-Miranda R., and Hernández-Carlos B. Tetrahedron 58 (2002) 3145
5. León-Rivera I., Mirón-López G., Molina-Salinas G.M., Herrera-Ruiz M., Estrada-Soto S., Gutiérrez M.C., Alonso-Cortes D., Navarrete-Vázquez G., Ríos M.Y., and Said-Fernández S. J. Nat. Prod. 71 (2008) 1686
6. + 1977.2361).
7. 4, and evaporated under reduced pressure. The aqueous layer was lyophilized, the residue was dissolved with methanol, and a white solid (glycosidic acid) was obtained after removal of solvent.
8. Noda N., Kogetsu H., Kawasaki T., and Miyahara K. Phytochemistry 29 (1990) 3565
9. Enríquez R.G., León I., Pérez F., Walls F., Carpenter K., Puzzuoli F., and Reynolds W.F. Can. J. Chem. 70 (1992) 1000
10. Escalante-Sánchez E., and Pereda-Miranda R. J. Nat. Prod. 70 (2007) 1029
11. R 15.2 min).
12. Lu Y., Luo J., Huang X., and Kong L. Steroids 74 (2009) 95
13. Reynolds W.F., and Enríquez R.G. J. Nat. Prod. 65 (2002) 221
14. The GC-MS system consisted of a HP 6890 gas chromatograph and a HP 5970 mass selective detector in the electron-ionization. GC conditions: 25 m × 0.2 mm HP-5 column; He, 1 mL/min; Oven temperature 40 °C, 2 min, 40-250 °C, Δ 15 °C/min, 250 °C 10 min; Injector temperature 300 °C; Interfase temperature 280 °C; split 1:40.
15. 3, 25.0; EDTA, 0.026 and glucose, 11.1, pH 7.4). Changes in tension were recorded by Grass-FT03 force transducers (Astromed, West Warwick, RI, USA) connected to a MP100 analyzer (Biopac Instruments, Santa Barbara, CA, USA). After equilibration, rings were contracted by noradrenaline (NA, 0.3 μM) and washed every 30 min for 2 h. The absence of endothelium was confirmed by the lack of a relaxing response to carbachol (1 μM). After precontraction with NA, the test samples (pure compounds, vehicle, and positive control) were added to the bath in a volume of 100 μL; then cumulative concentration-response curves were obtained for each ring. The relaxant effect of pure compounds and positive controls was determined by comparing the muscular tone of the contraction before and after addition of the test compounds.
16. Vanhoutte P.M. J. Cardiovasc. Pharmacol. 38 (2001) 796
17. 2 bubbling. Amino-oxyacetic acid at a concentration of 10.0 μM, was added to the medium to prevent GABA metabolism. After 5 min, slices were placed in 5 mL of the basal medium (Krebs-Ringer medium) in a well of microplate at 37 °C for 10 min. Next, pure compounds were added at a final concentration of 20.0 μg/mL and aliquots of 200 μL were taken out at 0.5, 1.0, 1.5, 2.0, and 3.0 min. At the end of the experiment, the content of GABA and glutamate into each collected aliquot was determined by HPLC, previous derivation with O-phthaldialdehyde. Protein content in brain slices was determined after its homogenization in 1 mL of water.
18. Herrera-Ruiz M., Gutiérrez C., Jiménez-Ferrer J.E., Tortoriello J., Mirón G., and León I. J. Ethnopharmacol. 112 (2007) 243
19. Antimycobacterial activity. The in vitro antimycobacterial activity of compounds 1 and 2 was measured as the minimal inhibitory concentration (MIC), and carried out using the modified microplate Blue Alamar assay (MABA). The concentrations of pure compounds ranged from 100.00 to 3.13 μg/mL. Rifampin was used as positive controls. All evaluations were carried out in duplicate.
20. Rivero-Cruz I., Acevedo L., Guerrero J.A., Martínez S., Bye R., Pereda-Miranda R., Franzablau S., Timmermann B.N., and Mata R. J. Pharm. Pharmacol. 57 (2005) 1117
21. Barnes C.C., Smalley M.K., Manfredi K.P., Kindscher K., Loring H., and Sheeley D.M. J. Nat. Prod. 66 (2003) 1457